COMORBIDITY OF CANCER AND TYPE 2 DIABETES: EPIDEMIOLOGYC STUDY IN A POPULATION OF OLDER ADULTS IN CÓRDOBA, ARGENTINA

REPOSSI G; PRIOTTO S; ASTORQUIZA P; BARBOSA MC; LOPEZ PM; FARÍAS S; DIAZ-GEREVINI GT

Paris

Congreso; World Congress of Controversies in Obesity and Diabetes 2023; 2023

Controversies in Obesity and Diabetes Group

Evidence show associations between cancer and type 2 diabetes mellitus (DM2).Aim: To study in a population of older adults whether the presence of DM2 affects the epidemiological parameters of cancer.Retrospective observational study (2006-2017), 4,574 medical record of San Ricardo Pampuri Center (Córdoba, Argentina) were analyzed (patients≥65 years). Cancer patients were grouped: with DM2 and without DM2. Poblational parameters were calculated and compared. Data were analyzed using ANOVA or chi-square test, p≤0.05. Confidentiality and anonymity were respected.Results: 56% women/44% men. Average age: 70,1. 42% patients were obese and 39.8% with DM2. 390 patients developing cáncer. Cancer prevalence=8.5%, mortality=27.5 ?, lethality=32%. Average survival: 2544.44 days. Sex or DM2 not modificate cáncer prevalences, but it higher in obese patients (58vs42%). Most frequent tumors: - Female: breast (0.44) and colon (0.10); -Male: prostate (0.36) and colon (0.17). Comparisons between groups with and without DM2: ?Prevalence (?): Higher in the group DM2: -Men: pancreas (1.31vs0.44), kidney (1.31vs0.44) and non-Hodgkin lymphoma (0.87vs0.44); -Women: breast (11.15vs8.31), pancreas (1.75vs0) and endometrium (1.53vs0.87). Higher in the group without DM2: -Men: prostate (7vs4.37), colon (3.28vs2.84) and bladder (1.97vs0.87);-Women: colon (3.06vs1.31), thyroid (1.09vs0.44) and melanoma (1.09vs0.22).?Age at diagnosis (years): colon (68.91vs75.87) and prostate (71.78vs77.74) cancer were found at earlier ages in mens with DM2. ?Mortality: Womens: the values were similar in both groups (RR:1.01; OR:1.02). Mens: mortality was lower for DM2 (RR:0.74; OR:0.57). -Tumors with highest mortality in DM2 patients were: breast>colon>prostate>pancreas. ?Lethality (%): higher in DM2 patients for gastric cancer (100vs50), while esophagus, colon, kidney and prostate were higher in the group without DM2. ?Survival (days): women without DM2 have higher survival like those with DM2 (4213.5vs1802.73).Conclusion: DM2 and cancer comorbidity significantly affects the parameters studied, mainly in women, increasing the prevalence of breast cancer and decreasing survival.